UBS Group
SNOA icon

UBS Group’s Sonoma Pharmaceuticals SNOA Stock Holding History

UBS Group’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.6K Buy
7,808
+7,802
+130,033% +$11.1K ﹤0.01% 8593
2026
Q1 		$13 Hold
6
– – ﹤0.01% 10318
2025
Q4 		$22 Sell
6
-102
-94% -$376 ﹤0.01% 10352
2025
Q3 		$419 Sell
108
-14,309
-99% -$56.3K ﹤0.01% 9686
2025
Q2 		$41K Buy
14,417
+12,565
+678% +$38K ﹤0.01% 7932
2025
Q1 		$4.06K Sell
1,852
-15,578
-89% -$42.1K ﹤0.01% 9154
2024
Q4 		$46.9K Buy
17,430
+4,700
+37% +$13.2K ﹤0.01% 7344
2024
Q3 		$39.1K Buy
12,730
+12,134
+2,036% +$61.9K ﹤0.01% 6976
2024
Q2 		$2.53K Buy
596
+591
+11,820% +$2.1K ﹤0.01% 8341
2024
Q1 		$17 Sell
5
-442
-99% -$1.43K ﹤0.01% 9054
2023
Q4 		$1.61K Buy
+447
New +$2.85K ﹤0.01% 8265
2023
Q1 		– Sell
-146
Closed -$3.28K – 10309
2022
Q4 		$3.28K Sell
146
-129
-47% -$4.59K ﹤0.01% 9538
2022
Q3 		$12K Buy
275
+241
+709% +$14.1K ﹤0.01% 8180
2022
Q2 		$2K Sell
34
-153
-82% -$9.8K ﹤0.01% 9611
2022
Q1 		$15K Buy
187
+115
+160% +$8.32K ﹤0.01% 7845
2021
Q4 		$7K Sell
72
-61
-46% -$6.52K ﹤0.01% 9165
2021
Q3 		$15K Buy
133
+33
+33% +$4.06K ﹤0.01% 7518
2021
Q2 		$15K Buy
+100
New +$15.7K ﹤0.01% 7648
2021
Q1 		– Sell
-56
Closed -$8K – 9425
2020
Q4 		$8K Sell
56
-3
-5% -$456 ﹤0.01% 7636
2020
Q3 		$10K Buy
+59
New +$9.08K ﹤0.01% 6862
2020
Q2 		– Sell
-30
Closed -$3K – 8326
2020
Q1 		$3K Sell
30
-105
-78% -$10.6K ﹤0.01% 7517
2019
Q4 		$12K Buy
135
+17
+14% +$1.7K ﹤0.01% 7192
2019
Q3 		$14K Sell
118
-80
-40% -$10.3K ﹤0.01% 6957
2019
Q2 		$31K Buy
198
+122
+161% +$18.7K ﹤0.01% 6309
2019
Q1 		$13K Sell
76
-20
-21% -$3.02K ﹤0.01% 6642
2018
Q4 		$12K Buy
96
+64
+200% +$12.8K ﹤0.01% 7148
2018
Q3 		$8K Buy
32
+3
+10% +$1.09K ﹤0.01% 7288
2018
Q2 		$13K Buy
29
+3
+12% +$1.96K ﹤0.01% 6998
2018
Q1 		$17K Buy
26
+1
+4% +$822 ﹤0.01% 6515
2017
Q4 		$24K Buy
25
+19
+317% +$16.3K ﹤0.01% 6413
2017
Q3 		$5K Sell
6
-3
-33% -$3.25K ﹤0.01% 7234
2017
Q2 		$12K Buy
9
+3
+50% +$3.7K ﹤0.01% 6653
2017
Q1 		$8K Sell
6
-5
-45% -$5.81K ﹤0.01% 6759
2016
Q4 		$10K Sell
11
-12
-52% -$9.95K ﹤0.01% 6925
2016
Q3 		$18K Buy
+23
New +$17.3K ﹤0.01% 6390
2016
Q2 		– Hold
0
– – – 7947
2016
Q1 		– Sell
-2
Closed -$1.86K – 8116
2015
Q4 		$2K Buy
+2
New +$2.13K ﹤0.01% 8026
2015
Q3 		– Sell
-5
Closed -$5.93K – 8610
2015
Q2 		$6K Sell
5
-15
-75% -$14.1K ﹤0.01% 7797
2015
Q1 		$15K Buy
20
+15
+300% +$12.7K ﹤0.01% 7291
2014
Q4 		$7K Buy
+5
New +$7.79K ﹤0.01% 8718

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
QWM
Quaker Wealth Management Moorestown, New Jersey $344M AUM 15.21% 1-Year Est. Return

UBS Group's SNOA Position: Q2 2026 in Review

UBS Group increased its Sonoma Pharmaceuticals (SNOA) stake by 130,033% in Q2 2026, buying an estimated $11.1K and bringing the position to 7,808 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8593.

UBS Group first reported a position in SNOA in Q4 2014 and has held it in 39 quarters since. The position peaked at $46.9K in Q4 2024. 12 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

  • UBS Group held 7,808 shares of Sonoma Pharmaceuticals worth $9.6K as of Q2 2026.
  • UBS Group bought 7,802 Sonoma Pharmaceuticals shares in Q2 2026, an estimated $11.1K.
  • Sonoma Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8593 holding.
  • UBS Group first reported a position in Sonoma Pharmaceuticals in Q4 2014 and has held it in 39 quarters since.
  • UBS Group's Sonoma Pharmaceuticals position peaked at $46.9K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.